8-K: Moderna Narrows 2025 Revenue, Cuts Expenses, Boosts Cash

Moderna reported a Q3 2025 net loss of $(0.2) billion on $1.0 billion revenue, narrowing its full-year revenue guidance while improving operating expense and year-end cash projections.

Summary

• Total revenue for the third quarter of 2025 was $1.0 billion, a 45% decrease from $1.9 billion in the same period in 2024.
• GAAP net loss for Q3 2025 was $(200) million, compared to net income of $13 million for Q3 2024.
• GAAP loss per share for Q3 2025 was $(0.51), compared to earnings per share of $0.03 for Q3 2024.
• COVID vaccine sales in Q3 2025 were $971 million, including $781 million from U.S. sales and $190 million from international sales.
• mRESVIA (RSV vaccine) sales in Q3 2025 were $2 million.
• The company narrowed its 2025 projected revenue range to $1.6 $2.0 billion, from a previous range of $1.5 $2.2 billion.
• Expected 2025 GAAP operating expenses were improved by $0.7 billion to a range of $5.2 $5.4 billion.
• Projected 2025 year-end cash balance was increased by $0.5 billion $1 billion to a range of $6.5 $7.0 billion.
• Moderna discontinued development of its congenital CMV program (mRNA-1647) after the Phase 3 study did not meet its primary efficacy endpoint.
• The Phase 3 study for the norovirus vaccine (mRNA-1403) will enroll a second Northern Hemisphere season (2025-2026) due to insufficient case accruals, delaying the readout.

Sentiment

Score: 6

Explanation: While Q3 2025 financial results showed a substantial decline in revenue and a shift to net loss compared to the prior year, the company demonstrated strong cost discipline, significantly improved its full-year operating expense and year-end cash projections. The discontinuation of the CMV program is a setback, but progress in other pipeline areas like oncology and rare diseases, along with new product approvals (mNEXSPIKE, mRESVIA) and manufacturing expansions, provide a balanced outlook.

Positives

• Improved 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 $5.4 billion, reflecting continued cost-reduction initiatives.
• Increased 2025 expected year-end cash balance by $0.5 billion $1 billion to a range of $6.5 $7.0 billion.
• Cost of sales as a percentage of net product sales improved to 21% in Q3 2025 from 28% in Q3 2024, driven by productivity gains and manufacturing efficiencies.
• Successful launch of mNEXSPIKE, the new COVID vaccine, in the U.S. for the 2025-2026 respiratory virus season.
• Received approval for its 2025-2026 formula for Spikevax in 40 countries and for mNEXSPIKE by the U.S. FDA for all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor.
• mRESVIA, the RSV vaccine, is approved for all adults aged 60 years and older in 40 countries, and in 31 of those countries for individuals 18-59 years of age at increased risk.
• Significant progress in oncology therapeutics, with the Phase 3 clinical trial for adjuvant melanoma (mRNA-4157) fully enrolled and two non-small cell lung cancer (NSCLC) Phase 3 studies enrolling.
• The propionic acidemia (PA) therapeutic (mRNA-3927) is in a registrational study and has reached target enrollment.
• The methylmalonic acidemia (MMA) therapeutic (mRNA-3705) has been selected by the FDA for the START pilot program, and a pivotal study design has been agreed upon, with a registrational study expected to start in 2026.
• Opened a state-of-the-art manufacturing and R&D facility in the UK, now licensed by the MHRA.
• Delivered the first made-in-Canada mRNA vaccines to Canadian provinces and territories.
• Australia manufacturing facility granted its Good Manufacturing Practice (GMP) license from the Therapeutic Goods Administration (TGA).

Negatives

• Total revenue for the third quarter of 2025 decreased 45% to $1.0 billion from $1.9 billion in the same period in 2024.
• Net product sales decreased $847 million, or 47%, primarily due to lower COVID vaccine sales and reduced vaccination rates year over year in the U.S.
• The third quarter of 2024 included an approximately $140 million positive adjustment related to prior-period sales provision estimates, which did not recur in 2025.
• Reported a net loss of $(200) million for the third quarter of 2025, compared to net income of $13 million for the third quarter of 2024.
• Reported a loss per share of $(0.51) for the third quarter of 2025, compared to earnings per share of $0.03 for the third quarter of 2024.
• Cash, cash equivalents and investments decreased to $6.6 billion as of September 30, 2025, from $7.5 billion as of June 30, 2025, primarily due to seasonal impacts on working capital.
• Discontinued development of its congenital CMV program (mRNA-1647) after the Phase 3 study did not meet its primary efficacy endpoint.
• The Phase 3 study for the norovirus vaccine (mRNA-1403) will require enrollment for a second Northern Hemisphere season (2025-2026) due to insufficient case accruals, delaying the timing of the Phase 3 readout.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and could cause actual results to differ materially.
• Reduced vaccination rates year over year for COVID-19 vaccines could continue to impact sales.
• Completion of certain government contracts and timing of deliveries can affect international revenue.
• Clinical trial failures, as demonstrated by the discontinuation of the congenital CMV program (mRNA-1647), are inherent risks in drug development.
• Insufficient case accruals in clinical trials, such as with the norovirus vaccine (mRNA-1403), can lead to delays in readouts and potential product launches.

Future Outlook

Moderna narrowed its 2025 projected revenue range to $1.6 $2.0 billion. The company expects to significantly improve its 2025 GAAP operating expenses to $5.2 $5.4 billion and projects a higher year-end cash balance of $6.5 $7.0 billion. Key pipeline milestones include completing submissions for the seasonal flu vaccine (mRNA-1010) by January 2026, awaiting further FDA guidance for the flu/COVID combination vaccine (mRNA-1083), and starting a registrational study for the MMA therapeutic (mRNA-3705) in 2026. The norovirus vaccine Phase 3 study will extend into a second season for case accruals.

Management Comments

• "We delivered strong commercial and financial performance in the third quarter, supported by COVID vaccine sales following the successful launch of mNEXSPIKE and a significant improvement in expected 2025 operating expenses from our ongoing cost-reduction initiatives." Stéphane Bancel, Chief Executive Officer of Moderna.
• "We remain highly focused on operational excellence and financial discipline to advance our pipeline and expand the reach of our commercial portfolio." Stéphane Bancel, Chief Executive Officer of Moderna.
• "We look forward to sharing further updates on our business and pipeline at our annual Analyst Day on November 20." Stéphane Bancel, Chief Executive Officer of Moderna.

Industry Context

Moderna's results reflect the evolving landscape of the COVID-19 vaccine market, with reduced vaccination rates impacting sales compared to prior years. The company is diversifying its portfolio with new respiratory vaccines (RSV, flu) and advancing therapeutics in oncology and rare diseases, aligning with a broader industry trend of leveraging mRNA technology beyond COVID-19. The discontinuation of the CMV program highlights the inherent risks and high failure rates in drug development, even for promising technologies. The focus on cost reduction and financial discipline is common for biotech companies transitioning from pandemic-driven growth to sustainable, diversified product pipelines.

Stakeholder Impact

• Shareholders: Potential impact from declining COVID vaccine sales and net loss, but mitigated by improved cost control, increased cash projections, and pipeline diversification. Discontinuation of the CMV program is a negative.
• Employees: Continued focus on "operational excellence and financial discipline" and "streamline operations" could imply ongoing efficiency efforts.
• Customers (Healthcare Providers/Patients): Availability of new COVID (mNEXSPIKE) and RSV (mRESVIA) vaccines in more countries. Discontinuation of the CMV vaccine means no new option for congenital CMV prevention.
• Suppliers: Lower sales volume and reduced manufacturing capacity utilization might affect some suppliers.
• Creditors: Improved cash position and financial discipline could be viewed positively.

Next Steps

• Host an Annual Analyst Day on November 20, 2025.
• Complete submissions for approval of seasonal flu vaccine (mRNA-1010) in the U.S., Canada, Australia, and Europe by January 2026.
• Refile flu/COVID combination vaccine (mRNA-1083) with Health Canada in 2025 and await further FDA guidance on refiling.
• Continue enrollment for the norovirus vaccine (mRNA-1403) Phase 3 study for a second Northern Hemisphere season (2025-2026) for additional case accruals.
• Start a registrational study for the methylmalonic acidemia (MMA) therapeutic (mRNA-3705) in 2026.

Key Dates

Recommendation

While Moderna reported a significant decline in Q3 2025 revenue and a net loss, reflecting the challenging post-pandemic vaccine market, the company demonstrated strong financial discipline by lowering operating expense projections and increasing its year-end cash outlook. The discontinuation of the CMV vaccine program is a setback, but the pipeline shows continued progress in oncology and rare diseases, with several programs advancing to late-stage trials or registrational studies. The successful launch of mNEXSPIKE and mRESVIA approvals indicate diversification efforts. Given the mixed financial performance but strategic pipeline advancements and improved cost management, a "hold" recommendation is appropriate as the company navigates its transition and executes on its broader mRNA platform strategy. Investors should monitor the progress of key pipeline assets and the market reception of new commercial products.

Keywords

Moderna, MRNA, Q3 2025, financial results, COVID vaccine, mNEXSPIKE, RSV vaccine, mRESVIA, mRNA-1010, seasonal flu vaccine, mRNA-1083, flu/COVID combination vaccine, norovirus vaccine, mRNA-1403, CMV vaccine, mRNA-1647, oncology, mRNA-4157, melanoma, NSCLC, mRNA-4359, rare disease, propionic acidemia, mRNA-3927, methylmalonic acidemia, mRNA-3705, operating expenses, revenue guidance, cash balance